Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;25(5):353-373.
doi: 10.2174/0113894501292755240304063020.

An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis

Bindu Soni  1 , Riya Shivgotra  1 , Karan Trehan  1 , Aashveen Chhina  1 , Muskaan Saini  1 , Subheet Kumar Jain  1   2 , Shubham Thakur  1
Affiliations
Review

An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis

Bindu Soni et al. Curr Drug Targets. 2024.

Abstract

Scalp psoriasis is a common manifestation of psoriasis that significantly impacts a patient's quality of life. About 80% of cases of psoriasis involve the scalp, making it the most frequently affected area of the body. The treatment of scalp psoriasis is particularly crucial because of its hard-to-treat nature and substantial adverse impacts on overall well-being. Along with the physical symptoms of discomfort and itching, psoriasis, especially when it affects the scalp, can cause severe psychological damage. Treating scalp psoriasis can be challenging due to its location and associated symptoms, such as scaling and pruritus, which is why various drugs have become widely used for refractory cases. Topical treatments like corticosteroids and vitamin D analogs manage scalp psoriasis by reducing inflammation and regulating skin cell growth. Tar-based shampoos, salicylic acid solutions, and moisturizers control scaling. Phototherapy with UVB light reduces inflammation. Severe cases may require systemic medications such as oral retinoids and immunosuppressants. While various therapies are accessible for scalp psoriasis, concerns arise due to their limited advantages and the absence of controlled studies assessing their effectiveness. Considering these challenges, there is a clear demand for innovative approaches to address this condition effectively. Recent advancements in topical therapies, phototherapy, systemic agents, and complementary therapies have shown promising results in managing scalp psoriasis. Also, the advent of biologics, specifically anti-IL-17 and anti-IL-23 drugs for scalp psoriasis, has seen significant improvements. The review highlights the lack of well-tolerated and effective treatments for scalp psoriasis and underscores the importance of further research in this area. The objective of this review is to clarify the different treatment options currently available or being investigated in clinical trials for managing scalp psoriasis.

Keywords: Scalp psoriasis; biologic treatment; phototherapy; quality of life; systemic treatment.; topical treatment.

PubMed Disclaimer

References

    1. Daniyal M.; Akram M.; Zainab R.; Munir N.; Shah S.M.A.; Liu B.; Wang W.; Riaz M.; Jabeen F.; Progress and prospects in the management of psoriasis and developments in phyto-therapeutic modalities. Dermatol Ther 2019,32(3) - DOI - PubMed
    1. Papp K.; Berth-Jones J.; Kragballe K.; Wozel G.; De La Brassinne M.; Scalp psoriasis: A review of current topical treatment options. J Eur Acad Dermatol Venereol 2007,21(9),1151-1160 - DOI - PubMed
    1. Vincenzi C.; Tosti A.; Efficacy and tolerability of a shampoo containing broad-spectrum cannabidiol in the treatment of scalp inflammation in patients with mild to moderate scalp psoriasis or seborrheic dermatitis. Skin Appendage Disord 2020,6(6),355-361 - DOI - PubMed
    1. Iversen L.; Conrad C.; Eidsmo L.; Costanzo A.; Narbutt J.; Pinter A.; Kingo K.; Rivera Diaz R.; Kolbinger F.; Nanna M.; Frueh J.A.; Jagiello P.; Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the study. J Eur Acad Dermatol Venereol 2023,37(5),1004-1016 - DOI - PubMed
    1. Lebwohl M.G.; Bachelez H.; Barker J.; Girolomoni G.; Kavanaugh A.; Langley R.G.; Paul C.F.; Puig L.; Reich K.; van de Kerkhof P.C.M.; Patient perspectives in the management of psoriasis: Results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol 2014,70(5),871-881.e30, 30 - DOI - PubMed

Substances